We report treatment results obtained with a modified Stanford V regimen in 32 patients with advanced Hodgkin's lymphoma (stage II bulky disease, III, IV). Treatment results were not superior to those achieved with conventional treatment (ABVD) in terms of complete remission and survival rates (progression-free survival and overall survival at 3 years: 66% and 91%, respectively).

Hohaus, S., Di Febo, A., Storti, S., Teofili, L., Voso, M.t., Leone, G. (2004). Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. HAEMATOLOGICA, 89(6), 751-752.

Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma

VOSO, MARIA TERESA;
2004-06-01

Abstract

We report treatment results obtained with a modified Stanford V regimen in 32 patients with advanced Hodgkin's lymphoma (stage II bulky disease, III, IV). Treatment results were not superior to those achieved with conventional treatment (ABVD) in terms of complete remission and survival rates (progression-free survival and overall survival at 3 years: 66% and 91%, respectively).
giu-2004
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Prednisone; Remission Induction; Survival Analysis; Vinblastine; Vincristine
Hohaus, S., Di Febo, A., Storti, S., Teofili, L., Voso, M.t., Leone, G. (2004). Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. HAEMATOLOGICA, 89(6), 751-752.
Hohaus, S; Di Febo, A; Storti, S; Teofili, L; Voso, Mt; Leone, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/115744
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact